Thyroid tumors: Histological classification and genetic factors involved in the development of thyroid cancer

Endocrine Regulations

Volumn 39, Issue 3, 2005, Pages 73-83

  Liska, J ^a,b   Altanerova, V ^c   Galbavy, S ^a,d   Stvrtina, S ^a   Brtko, J ^a,b  

^a Physics and Informatics   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

^d St Elisabeth' Oncological Institute   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; FAMILIAL CANCER; FOLLICULAR CARCINOMA; HEREDITY; HISTOPATHOLOGY; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE RET; PAPILLARY CARCINOMA; PROGNOSIS; THYROID ADENOMA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID TUMOR; WORLD HEALTH ORGANIZATION; ADENOCARCINOMA; CARCINOMA; CLASSIFICATION; FEMALE; GENETICS; MALE; MEDULLARY CARCINOMA; MUTATION; ONCOCYTOMA; PATHOLOGY; REVIEW; THYROID FOLLICULAR CARCINOMA;

DNA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; CARCINOMA; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY, FOLLICULAR; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MUTATION; THYROID NEOPLASMS;

EID: 33644866495     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. ALSANEA O.: Familial nonmedullary thyroid cancer. Curr Treat Options Oncol 1, 345-351, 2000
2. BERNDT I, REUTER M, SALLER B et al: A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83, 770-774, 1998
3. BOLINO A, SCHUFFENECKER I, LUO Y et al: RET mutations in exons 13 and 14 of FMTC patients. Oncogene 15, 2415-2419, 1995
4. BRANDI ML, GAGEL RF, ANGELI A et al: Guidelines for diagnosis and therapy of MEN type 1 and 2. J Clin Endocrinol Metab 86, 5658-5671, 2001
5. BRTKO J, BOBALOVA J, PODOBA J, SCHMUTZLER C, KOHRLE J: Thyroid hormone receptors and type I iodothyronine 5′-deiodinase activity of human toxic adenomas and benigncold nodules, Exp Clin Endocrinol Diabetes 110, 166-170, 2002
6. BURMAN KD, RINGEL VD, WARTOFSKY L: Unusual types of thyroid neoplasms. Endocrinol. Metab Clin North Am 25, 49-68, 1996
7. CAILLOU B: Follicular carcinoma. Arch Anat Cytol Pathol 46, 39-44, 1998
8. CHAN JKC: Tumors of the thyroid and parathyroid glands in: Diagnostic histopathology of tumors, Vol.2. FLETCHER CDM, Churchil Livingstone, London 959 - 1038, 2001
9. CARLSON KM, DOU S, CHI D et al: Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U.S.A.; 91, 1579-1583, 1994
10. COLLINI P, SAMPIETRO G, ROSAI J, PILOTTI S: Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch 442, 71-76, 2002.
11. CORMACK DH: The Endocrine System. In: Essential histology. JB Lippincot Company, Philadelphia 339-356, 1993
12. CORVILAIN B: The natural history of thyroid autonomy and hot nodules. Ann Endocrinol 64, 17-22, 2003
13. DEAN DS, HAY DH: Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7, 229-239, 2000
14. ENG C, CLAYTON D, SCHUFFENECKER I et al: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276, 1575-1579, 1996
15. FATTORUSO O, QUADRO L, LIBROIA A et al: A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET protooncogene in two families affected by familial medullary thyroid carcinoma. Hum Mutat, Suppl 1, 167-171, 1998
16. FIGGE J: Epidemiology of thyroid cancer. In: WARTOFSKY L ed. Thyroid Cancer: a comprehensive guide to clinical management. Totowa: Humana Press 77-83, 1999
17. GAGEL RF, GOEPFERD H, CALLENDER DL: Changing concepts in the pathogenesis and management of thyroid gland carcinoma. Cancer J Clin 46, 261-283, 1996
18. GILLILAND FD, HUNT WC, MORRIS DM, KEY RC: Prognostic factors for thyroid carcinoma: A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79, 564-573, 1997
19. GIMM O, MARSH DJ, ANDREW SD et al.: Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab; 82, 3902-3904, 1997
20. GOULD VE, SOMMERS SC: Endocrine system. In: Pathology, pp. 1118-1177. JB Lippincot, Philadelphia 1988
21. HOPPNER W, RITTER MM: A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet; 6, 587-590 1997
22. HOFSTRA RM, FATTORUSO O, QUADRO L et al: A novel point mutation in the intracellular domain of the ret protooncogene in the family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82, 4176-4178, 1997
23. HOPPNER W, DRALLE H, BRABANT G: Duplication of 9 base pairs in the critical cysteine-rich domain of the RET protooncogene causes multiple endocrine neoplasia type 2A. Hum Mutat Suppl 1, 128-130, 1998
24. KIMURA ET, NIKIFOROVA MN, ZHU Z et al: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457, 2003
25. KITAMURA Y, GOODFELLOW PJ, SHIMIZU K et al: Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene 14, 3103-3106, 1997
26. KROLL TG: Molecular rearrangement and morphology in thyroid cancer. Am J Path 160, 1941-1944, 2002.
27. LIVOLSI VA: Thyroid. In: Histology for Pathologists, Ed: STERNBERG SS, Raven Press, Ltd New York 301-310, 1992
28. MALCHOFF CD, MALCHOFF DM: The genetics of hereditary nonmedullary thyroid carcinoma. J Clin Endocrinol Metab 87, 2455-2459, 2002
29. MAZZAFERRI EL, KLOOS RT: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86, 1447-1463, 2001
30. MCKAY JD, LESUEUR F, JONARD L et al: Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 69, 440-446, 2001
31. MIYAUCHI A, FUTAMI H, HAI N et al: Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 90, 1-5, 1999
32. MULLIGAN LM,,MARSH DJ, ROBINSON BG et al: Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238, 343-346, 1995
33. O'RIORDAIN DS, O'BRIEN T, WEAVER AL et al: Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116, 1017-1023, 1994
34. PAL T, VOGL FD, CHAPPUIS PO et al: Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab. 86, 5307-5312, 2001
35. PASINI A, GENESTE O, LEGRAND P et al: Oncogenic activation by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 15, 393-402, 1997
36. POTURNAJOVA M, ALTANEROVA V, KOSTALOVA L et al: Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome. J Mol Med 83, 287-295, 2005
37. SALABE GB: Pathogenesis of thyroid nodules: histological classification? Biomedicine and Pharmacotherapy 55, 39-53, 2001
38. SANTORO M, CARLOMAGNO F, ROMANO A et al: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267, 381-383, 1995
39. SCHUFFENECKER I, VIRALLY-MONOD M, BROHET R et al: Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83, 487-491, 1998
40. SHERMAN SI: Thyroid carcinoma. Lancet 361, 501-511, 2003
41. SHERMAN SI: Anaplastic carcinoma: clinical aspects. In: WARTOFSKY L ed. Thyroid Cancer: a comprehensive guide to clinical management. Totowa: Humana Press 319-325, 1999
42. SHRODER S, BOCKER W, BAISCH H et al: Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 61, 806-816, 1988
43. SMITH DP, HOUGHTON C, PONDER BA: Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15, 1213-1217, 1997
44. TESSITORE A, SINISI AA, PASQUALI D et al: A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. J Clin Endocrinol Metab. 84, 3522-3527, 1999
45. THOMPSON LD, WIENEKE JA, PAAL E et al: A clinicopathological study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 91, 505-524, 2001
46. WOLFE HJ, DELELLIS RA: Familial medullary thyroid carcinoma and C cell hyperplasia. Clin Endocrinol Metab 10, 351-365, 1981